JP2024520898A5 - - Google Patents
Info
- Publication number
- JP2024520898A5 JP2024520898A5 JP2023569779A JP2023569779A JP2024520898A5 JP 2024520898 A5 JP2024520898 A5 JP 2024520898A5 JP 2023569779 A JP2023569779 A JP 2023569779A JP 2023569779 A JP2023569779 A JP 2023569779A JP 2024520898 A5 JP2024520898 A5 JP 2024520898A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- sbcma
- level
- therapy
- blood sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163187344P | 2021-05-11 | 2021-05-11 | |
| US63/187,344 | 2021-05-11 | ||
| PCT/US2022/072247 WO2022241430A1 (en) | 2021-05-11 | 2022-05-11 | Methods and compositions for monitoring the treatment of relapsed and/or refractory multiple myeloma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024520898A JP2024520898A (ja) | 2024-05-27 |
| JP2024520898A5 true JP2024520898A5 (enExample) | 2025-05-19 |
Family
ID=82399377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023569779A Pending JP2024520898A (ja) | 2021-05-11 | 2022-05-11 | 再発性及び／又は難治性多発性骨髄腫の治療をモニタリングするための方法及び組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20220373550A1 (enExample) |
| EP (1) | EP4337962A1 (enExample) |
| JP (1) | JP2024520898A (enExample) |
| KR (1) | KR20240005919A (enExample) |
| CN (1) | CN117295949A (enExample) |
| AU (1) | AU2022273326A1 (enExample) |
| CA (1) | CA3219969A1 (enExample) |
| MX (1) | MX2023013412A (enExample) |
| TW (1) | TW202309522A (enExample) |
| WO (1) | WO2022241430A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| PH12022553023A1 (en) | 2020-05-11 | 2024-03-04 | Janssen Biotech Inc | Methods for treating multiple myeloma |
| WO2023081705A1 (en) | 2021-11-03 | 2023-05-11 | Janssen Biotech, Inc. | Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies |
| WO2024168192A1 (en) * | 2023-02-10 | 2024-08-15 | Celgene Corporation | Assessment of bcma in biological samples |
| CN121358492A (zh) * | 2023-04-19 | 2026-01-16 | 詹森生物科技公司 | 用于治疗多发性骨髓瘤的方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| JP3720353B2 (ja) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| AU6232899A (en) | 1999-10-06 | 2001-05-10 | Campina Melkunie B.V. | Use of transforming growth factor beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa |
| UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| CA2438682A1 (en) | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| JP2011507519A (ja) | 2007-12-19 | 2011-03-10 | セントコア・オーソ・バイオテツク・インコーポレーテツド | ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法 |
| KR101589785B1 (ko) | 2009-03-10 | 2016-01-28 | 바이오젠 엠에이 인코포레이티드 | 항-ｂｃｍａ 항체 |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| WO2017031104A1 (en) | 2015-08-17 | 2017-02-23 | Janssen Pharmaceutica Nv | Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof |
| TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| KR102512934B1 (ko) | 2016-08-10 | 2023-03-23 | 레전드 바이오테크 아일랜드 리미티드 | Bcma를 표적으로 하는 키메라 항원 수용체 및 이들의 이용 방법 |
| US20220003772A1 (en) * | 2018-10-31 | 2022-01-06 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
| CA3160178A1 (en) * | 2019-11-05 | 2021-05-14 | Celgene Corporation | Uses of anti-bcma chimeric antigen receptors |
-
2022
- 2022-05-10 TW TW111117430A patent/TW202309522A/zh unknown
- 2022-05-11 WO PCT/US2022/072247 patent/WO2022241430A1/en not_active Ceased
- 2022-05-11 KR KR1020237042423A patent/KR20240005919A/ko active Pending
- 2022-05-11 AU AU2022273326A patent/AU2022273326A1/en not_active Abandoned
- 2022-05-11 JP JP2023569779A patent/JP2024520898A/ja active Pending
- 2022-05-11 EP EP22737692.8A patent/EP4337962A1/en active Pending
- 2022-05-11 CA CA3219969A patent/CA3219969A1/en active Pending
- 2022-05-11 CN CN202280034423.8A patent/CN117295949A/zh active Pending
- 2022-05-11 US US17/742,076 patent/US20220373550A1/en not_active Abandoned
- 2022-05-11 MX MX2023013412A patent/MX2023013412A/es unknown
-
2025
- 2025-07-25 US US19/281,154 patent/US20250362298A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Lipopolysaccharide-mediated chronic inflammation promotes tobacco carcinogen–induced lung cancer and determines the efficacy of immunotherapy | |
| Zhou et al. | Hepatic NOD2 promotes hepatocarcinogenesis via a RIP2-mediated proinflammatory response and a novel nuclear autophagy-mediated DNA damage mechanism | |
| Chen et al. | Silence of long noncoding RNA NEAT1 exerts suppressive effects on immunity during sepsis by promoting microRNA‐125‐dependent MCEMP1 downregulation | |
| Marks et al. | Innate immunity in inflammatory bowel disease: a disease hypothesis | |
| Munari et al. | Cytokine BAFF released by Helicobacter pylori–infected macrophages triggers the Th17 response in human chronic gastritis | |
| KR20160044030A (ko) | 종양 치료용 항-ｂ7-ｈ1 항체 | |
| US11730789B2 (en) | Cell penetrating antibodies | |
| Zhou et al. | Diverse roles of macrophages in intraocular neovascular diseases: a review | |
| Wang et al. | Silencing of SAA1 inhibits palmitate-or high-fat diet induced insulin resistance through suppression of the NF-κB pathway | |
| CN112912403A (zh) | 治疗肿瘤的方法 | |
| Jarneborn et al. | Tofacitinib treatment aggravates Staphylococcus aureus septic arthritis, but attenuates sepsis and enterotoxin induced shock in mice | |
| IL275438B1 (en) | Biomarkers of methotrexate-induced immune tolerance | |
| Xie et al. | Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-γ/NSDHL/SREBP1/TGF-β1 axis in hepatocellular carcinoma | |
| CN106573056A (zh) | 用于诊断和治疗炎症性肠病的方法和组合物 | |
| Moon et al. | Interleukin-2 improves insulin sensitivity through hypothalamic sympathetic activation in obese mice | |
| Zhou et al. | The present roles and future perspectives of Interleukin-6 in biliary tract cancer | |
| Xiao et al. | Streptococcus may aggravate inflammatory damage in chronic nephritis via the chemotaxis of Th22 cells | |
| Kadota et al. | Perioperative management in myasthenia gravis: republication of a systematic review and a proposal by the guideline committee of the Japanese Association for Chest Surgery 2014 | |
| Xu et al. | Il-17 imbalance promotes the pyroptosis in immune-mediated liver injury through stat3-ifi16 axis | |
| Wang et al. | A bifunctional antibody targeting PD-1 and TGF-β signaling has antitumor activity in combination with radiotherapy and attenuates radiation-induced lung injury | |
| Çiçek et al. | Evaluation of neutrophil/lymphocyte and platelet/lymphocyte ratios in sudden sensorineural hearing loss and relationship with hyperbaric oxygen therapy | |
| Perrichet et al. | Cancer cell-derived IL-1β reverses chemo-immunotherapy resistance in non-small cell lung cancer | |
| Qiao et al. | Decreased expression levels of complement regulator CD55 contribute to the development of bullous pemphigoid | |
| CN113454114B (zh) | 治疗癌症的药物组合 | |
| WO2019241742A1 (en) | Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer |